These data indicate that the combination of CBDCA and anti-PD-1 increases the abundance of tumor infiltrating CD8+ T cells and tumor-specific CD8+ T cells in the secondary tumors in a setting of immunochemotherapy before surgery for TNBC models. The gene discussed is CD8A; the disease is neoplasm.